Equity Research Health Information Services

Should You Buy Phreesia, Inc. Stock in 2026?

By CirclFi Research Team · · Updated · 7/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Phreesia, Inc. (PHR) scores a robust 8.4/10 on our 32-signal Quality of Company framework. At the current market price of $10.25 and a $636M market cap, our analysis maps this fundamental strength against 13 institutional-grade models to determine if a sufficient margin of safety exists.

The short answer: 4 of 7 CirclFi valuation models project upside for Phreesia, Inc. (PHR) at $10.25 — the model consensus leans bullish, with a Quality Score of 8.4/10 and Value-Trap risk of 35/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 4 of 7 models see upside — majority bullish
  • Quality Score: 8.4/10 — Excellent — top-tier fundamentals
  • Value Trap Risk: 35/100 — Low — manageable risk
  • Fair Value Range: $2.09 – $19.72 (842% spread)

Bullish Models

4 / 7

Bearish Models

3 / 7

Quality Score

8.4 /10

Excellent — top-tier fundamentals

Value Trap Risk

35 /100
Low

Low — manageable risk

Model Consensus

7 /13
Active Models

Avg. confidence: 47%

What Is the Investment Case for Phreesia, Inc. (PHR) in 2026?

What Is the Bull Case vs the Bear Case for Phreesia, Inc. (PHR)?

Bull case versus bear case for Phreesia, Inc. (PHR) at $10.25, derived from 7 active CirclFi valuation models on 2026-10-07.
Bull case — $19.72 target (+92.4%) Bear case — $2.09 target (-79.6%)
According to the CirclFi Quality of Company (QOC) framework, Phreesia, Inc.'s rating of 8.4/10 signals strong fundamentals — high-quality businesses tend to compound value more reliably. According to the CirclFi Deep Alpha Valuation Engine, the Dynamic NAV model sees the stock as overvalued with a fair value of $2.09 (-79.6%), suggesting that the market price embeds overly optimistic growth assumptions.
According to the CirclFi Deep Alpha Valuation Engine, the FTNN Topology model targets a fair value of $19.72 (+92.4%), anchoring the bull case with a methodology that provides a differentiated analytical lens. According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +172.0% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology.

How Does PHR Compare to Its Health Information Services Peers?

VASO Vaso Corporation
8.5
CCLD CareCloud, Inc.
8.4
SPOK Spok Holdings, Inc.
8.6
OPRX OptimizeRx Corporati
8.3
HSTM HealthStream, Inc.
8.7
GDRX GoodRx Holdings, Inc
8.1
DH Definitive Healthcar
7.0
SOPH SOPHiA GENETICS SA
5.9

Valuation data pages: VASO · CCLD · SPOK · OPRX · HSTM · GDRX · DH · SOPH · MSPR · DOCS · HQY

See full Health Information Services rankings →

Which Other Stocks Score Like PHR on Quality?

Closest companies to PHR’s Quality of Company score of 8.4/10, across all industries.

Why Do CirclFi’s 7 Models Disagree on PHR?

Spread

842%

Fair Value Range

$2.09 – $19.72

A 842% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

FTNN

$19.72 (+92.4%)

Most Bearish

Dynamic NAV

$2.09 (-79.6%)

What Are the Biggest Risks of Buying PHR Stock?

Model Disagreement

842% spread signals high variance in projections.

Macro/Sector Risk

Health Information Services headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View PHR Data Page →

So Is Phreesia, Inc. (PHR) Worth Buying in 2026?

Phreesia, Inc. at $10.25 is a genuine coin-flip in our framework. The 3–3 bull-bear split across 7 models, +172.0% model spread, and median fair value of $10.74 (+4.8% vs price) argue for a watchlist position rather than a high-conviction bet. Quality at 8.4/10 adds some comfort to the mix.

These are quantitative model outputs, not investment recommendations. Phreesia, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About PHR Stock?

Should I buy PHR stock right now?

Based on CirclFi's multi-model analysis, 4 of 7 models see upside for PHR at $10.25. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 8.4/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Phreesia, Inc.?

Key risks include: limited model coverage (7/13 active), reducing analytical confidence; wide model disagreement (842% spread), signaling high uncertainty; general market and sector-specific risks affecting Health Information Services companies. Always diversify and consult a financial advisor.

How does PHR compare to its competitors?

Among Health Information Services peers, PHR holds a Quality Score of 8.4/10. Comparable companies include VASO (QOC 8.5), CCLD (QOC 8.4), SPOK (QOC 8.6). The relative ranking helps investors identify whether PHR offers better fundamental quality than alternatives in the same sector.

Is PHR a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. PHR's Quality Score of 8.4/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.

What price should I buy PHR at?

CirclFi does not provide target buy prices or price alerts. However, our 7 active models produce fair value estimates ranging from $2.09 to $19.72. At $10.25, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for PHR.

View PHR Data Page Full Terminal — $60/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →